Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Orforglipronlilly.com · Low evidenceFoundayo™ (orforglipron) is an oral GLP-1 pill developed by Eli Lilly and Company for weight management and obesity care. It is the only GLP-1 pill approved by the FDA, designed to support journalists and content creators with official visuals and background materials.
Eli Lilly and CompanyOrforglipronParse Score